HLA-DPB1 supertype-associated protection from childhood leukaemia: Relationship to leukaemia karyotype and implications for prevention

Cancer Immunology, Immunotherapy

Volumn 57, Issue 1, 2008, Pages 53-61

  Taylor, Malcolm ^a   Harrison, Christine ^b   Eden, Tim ^a   Birch, Jillian ^a   Greaves, Mel ^c   Lightfoot, Tracy ^d   Hussain, Adiba ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Childhood leukaemia; HLA DPB1; Hyperdiploidy; Immune response; Karyotype; Prevention; TEL AML1

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PREVENTION; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE FUSION; GENE TRANSLOCATION; GENETIC RISK; GENOTYPE; HLA DPB1 GENE; HUMAN; IMMUNE RESPONSE; KARYOTYPE; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; PROTECTION; TETRASOMY;

CHILD; CHROMOSOME ABERRATIONS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DP ANTIGENS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT, NEWBORN; KARYOTYPING; MALE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 35748956713     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0349-5     Document Type: Article

References (59)

1. Greaves MF, Colman SM, Beard MEJ, Bradstock K, Cabrera ME, Chen P-M, Jacobs P, Lam-Po-Tang PRL, MacDougal LG, Williams CKO, Alexander FE (1993) Geographical distribution of acute lymphoblastic leukaemia subtypes: second report of the collaborative study group. Leukemia 7:27-34
2. Buckley JD, Buckley CM, Ruccione K, Sather HN, Waskerwitz MJ, Woods WG, Robison LL (1994) Epidemiological characteristics of childhood acute leukemia. Analysis by immunophenotype. Leukemia 8:856-864
3. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coeburgh J-M, Lacour B, Parkin M (2004) Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study. Lancet 364:2097-2105
4. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG (1995) Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukaemia. Proc Nat Acad Sci 92:4917-4921
5. Romana SP, Mauchauffé M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA (1995) The t (12; 21) of acute lymphoblastic leukaemia results in a tel-AML1 gene fusion. Blood 85:3662-3670
6. Raimondi SC, Pui C-H, Hancock ML, Behm FG, Filatov L, Rivera GK (1996) Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 10:213-224
7. Paulsson K, Mörse H, Fioretos T, Behrendtz M, Strömbeck B, Johanssen B (2005) Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukaemia. Genes Chromosomes Cancer 44:113-122
8. Poirel H, Lacronique V, Mauchauffé M, Le Coniat M, Raffoux E, Daniel M-T, Erickson P, Drabkin H, MacLeod RAF, Drexler HG, Ghysdael J, Berger R, Bernard OA (1998) Analysis of TEL proteins in human leukemias. Oncogene 16:2895-2903
9. McLean TW, Ringold S, Neuberg D, Stegmeier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub TR (1996) TEL-AML1 dimerizes and is associated with a favourable outcome in childhood acute lymphoblastic leukaemia. Blood 88:4252-4258
10. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui C-H, Downing JR, Behm FG (1997) Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukaemia treated with antimetabolite-based therapy: a Pediatric Oncology Group Study. Blood 89:1143-1146
11. Onadera N, McCabe NR, Rubin CM (1992) Formation of a hyperdiploid karytoype in childhood acute lymphoblastic leukemia. Blood 80:203-208
12. Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, Broadfield ZJ, Harris RL, Taylor KE, Gibson BES, Hann IM, Hill FGH, Kinsey SE, Eden TO, Mitchell CD, Harrison CJ (2003) Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 102:2756-2762
13. Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143
14. Ford AM, Bennett CA, Price CM, Bruin MCA, Van Wering ER, Greaves M (1998) Fetal origins of the TEL-AML1 fusion gene in identical twins with leukaemia. Proc Nat Acad Sci 95:4584-4588
15. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, Saha V, Biondi A, Greaves MF (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354:1499-1503
16. Wiemels JL, Ford AM, Van Wering AM, Postma ER, Greaves M (1999) Protracted and variable latency of acute lymphoblastic leukaemia after TEL-AML1 gene fusion in utero. Blood 94:1057-1062
17. Maia AT, Tussiwand R, Cazzaniga G, Rebulla P, Colman S, Biondi A, Greaves M (2004) Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukaemia in cord blood. Genes Chromosomes Cancer 40:38-43
18. Yotdna P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 102:455-462
19. Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y (1999) Augmentation of immune responses by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 54:153-161
20. Taylor GM, Dearden S, Ravetto P, Ayres M, Watson P, Hussain A, Greaves M, Alexander F, Eden OB, UKCCS Investigators (2002) Genetic susceptibility to childhood common acute paediatric lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet 11:1585-1597
21. UK Childhood Cancer Study Investigators (2000) The United Kingdom Childhood Cancer Study: objectives, materials and methods. Br J Cancer 82:1073-1102
22. Rooney DE, Czepulkowski BH (1992) Human cytogenetics. A practical approach. Vol II. Malignancy and acquired abnormalities. 2nd edn. Oxford University, New York
23. Harrison CJ, Martineau M, Secker-Walker LM (2001) The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 113:3-10
24. Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL, et al. (2005) Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 129:520-530
25. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffé M, Jonveaux P, Macintyre EA, Berger R, Bernard OA (1995) High frequency of t (12; 21) in childhood B-lineage acute lymphoblastic leukaemia. Blood 86:4263-4269
26. POPGENE version 1.31: Microsoft Window-based freeware for population genetic analysis: http://www.ualberta.ca/∼fyeh
27. LINKUTIL: http://linkage.rockefeller.edu/soft/linkutil/
28. Postuma EFM, Falkenburg JHF, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GMT, D'Amaro J, Oudshoorn M, v. Biezen JH, Hermans J, Willemze R, Niederwieser D, on behalf of the Chronic Leukaemia Working Party of the EBMT. Blood 93:3863-3865
29. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, Gahery-Segard H, Guillet J-G, Menez A, Georges B, Maillere B (2002) HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 169:6928-6934
30. Arroyo J, Alvarez AM, Nombela C, Sanchez-Perez M (1995) The role of HLA- DPβ residue 69 in the definition of antibody-binding epitopes. Hum Immunol 43:219-226
31. Diaz G, Catalfamo M, Coiras MT, Alvarez AM, Jaraquemamda D, Nombela C, Sanchez-Perez M, Arroyo J (1998). HLA- DPβresidue 69 plays a crucial role in allorecognition. Tissue Antigens 52:27-36
32. Berretta F, Butler RH, Diaz G, Sanarico N, Arroyo J, Fraziano M, Aichinger G, Wucherpfennig KW, Colizzi V, Saltini C, Amicosante M (2003) Detailed analysis of the effects of Glu/Lys b69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens 62:459-471
33. 69 HLA-DPB1 and -DPA1 alleles. J Immunol 163:1647-1653
34. Doytchinova IA, Flower DR (2005) In silico identification of supertypes LA ligand HLA-Ligand for class II MHCs. J Imunol 174:7085-7095
35. Diaz G, Amicosante M, Jaraquemada D, Butler RH, Guillen MV, Sanchez M, Nombela C, Arroyo J (2003) Functional analysis of HLA-DP polymorphism: a crucial role for DPβ residues 9, 11, 35, 55, 69, and 84-87 in T cell allorecognition and peptide binding. Int Immunol 15:565-576
36. Diaz G, Canas B, Vazquez J, Nombela C, Arroyo J (2005) Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics 56:754-759
37. Sette A, Sidney J (1998) HLA supertypes and supermotfis: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478-482
38. Sham PC, Curtis D (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59:97-105
39. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research, vol 1 IARC Scientific Publications, Lyon
40. Perneger TV (1998) What's wrong with Bonferroni adjustments. Br Med J 316:1236-1238
41. Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chessells JM, Hann IM, Hill FGH, Gibson BES on behalf of the Medical Research Council Childhood Leukaemia Working Party (2000) Long-terrm follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukemia 14:2307-2320
42. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S (2000) AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematoligica 85:362-366
43. Mikhail FM, Serry KA, Hatem N, Mourad ZI, Farawela HM, El Kaffash DM, Coignet L, Nucifora G (2002) AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia 16:658-668
44. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561
45. Chan LC, Pegram SM, Greaves MF (1985) Contribution of immunophenotype to the classification and differential diagnosis of acute leukaemia. Lancet 325:475-479
46. Jennings CD, Foon KA (1997) Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 90:2863-2892
47. Alessandri AJ, Reid GSD, Bader SA, Massing BG, Sorensen PHB, Schultz KR (2002) ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol 116:266-272
48. Ibisch C, Gallot G, Vivien R, Diez E, Jotereau F, Garand R, Vie H (1999) Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplant 23:1153-1159
49. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognised by T cells. Cancer Immunol Immunother 50:3-15
50. Niegemann E, Wehner S, Kornhuber B, Schwabe D, Ebener U (1999) Wt1 gene expression in childhood leukemias. Acta Haematolgica 102:72-76
51. Spanaki A, Linardakis E, Perdikogianni C, Stiakaki E, Morotti A, Cilloni D, Kalmanti M (2007) Quantitative assessment of WT1 expression in diagnosis of childhood acute leukaemia. Leuk Res 31:569-575
52. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilm's tumor gene (WT1) product. Immunogenetics 51:99-107
53. Dubrovina ES, Doubrovin MM, Lee S, Shieh J-H, Heller G, Pamer E, O'Rielly RJ (2004) In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res 10:7207-7219
54. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijn Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, Yasukawa M (2005) Direct recognition and lysis of leukaemia cell by WT1-specific CD4+ T lymphocytes in an HLA-restricted manner. Blood 106:1415-1418
55. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M (2006) Wilm's tumor gene (WT1) expression in childhood acute lymphoblastic leukaemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20: 254-263
56. Greaves M (2006) Infection, immune responses, and the aetiology of childhood leukaemia. Nat Rev Genet 6:193-203
57. Spadaro M, Lanzardo S, Curcio C, Forni G, Cavallo F (2004) Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 53:204-216
58. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, Hows JM, Navarette C, Greaves M (2002) Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Nat Acad Sci 99:8242-8247
59. Ravetto PF, Agarwal R, Chiswick ML, D'Souza SW, Eden OB, Taylor GM (2003) Absence of leukaemic fusion gene transcripts in preterm infants exposed to diagnostic x rays. Arch Dis Child 88:F237-F244